532 related articles for article (PubMed ID: 9075625)
21. The effect of hormone replacement therapy in postmenopausal women on urinary C-telopeptide and N-telopeptide of type I collagen, new markers of bone resorption.
Taga M; Uemura T; Minaguchi H
J Endocrinol Invest; 1998 Mar; 21(3):154-9. PubMed ID: 9591210
[TBL] [Abstract][Full Text] [Related]
22. Changes in urinary excretion of type-I collagen cross-linked C-telopeptide and N-telopeptide in perimenopausal women.
Taga M; Shirashu K; Minaguchi H
Horm Res; 1998; 49(2):86-90. PubMed ID: 9485177
[TBL] [Abstract][Full Text] [Related]
23. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study.
Garnero P; Hausherr E; Chapuy MC; Marcelli C; Grandjean H; Muller C; Cormier C; Bréart G; Meunier PJ; Delmas PD
J Bone Miner Res; 1996 Oct; 11(10):1531-8. PubMed ID: 8889854
[TBL] [Abstract][Full Text] [Related]
24. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
Marcus R; Holloway L; Wells B; Greendale G; James MK; Wasilauskas C; Kelaghan J
J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
[TBL] [Abstract][Full Text] [Related]
25. Urinary bone resorption markers in monitoring treatment of symptomatic osteoporosis.
Parviainen MT; Jääskeläinen K; Kröger H; Arnala I; Alhava E
Clin Chim Acta; 1999 Jan; 279(1-2):145-54. PubMed ID: 10064126
[TBL] [Abstract][Full Text] [Related]
26. Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy?
Langdahl BL; Loft AG; Møller N; Weeke J; Eriksen EF; Mosekilde L; Charles P
J Bone Miner Res; 1997 Jan; 12(1):78-88. PubMed ID: 9240729
[TBL] [Abstract][Full Text] [Related]
27. Relationship between serum leptin concentrations and bone mineral density as well as biochemical markers of bone turnover in women with postmenopausal osteoporosis.
Shaarawy M; Abassi AF; Hassan H; Salem ME
Fertil Steril; 2003 Apr; 79(4):919-24. PubMed ID: 12749431
[TBL] [Abstract][Full Text] [Related]
28. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism.
Guo CY; Thomas WE; al-Dehaimi AW; Assiri AM; Eastell R
J Clin Endocrinol Metab; 1996 Oct; 81(10):3487-91. PubMed ID: 8855790
[TBL] [Abstract][Full Text] [Related]
29. Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption.
Clemens JD; Herrick MV; Singer FR; Eyre DR
Clin Chem; 1997 Nov; 43(11):2058-63. PubMed ID: 9365389
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption.
Eastell R; Robins SP; Colwell T; Assiri AM; Riggs BL; Russell RG
Osteoporos Int; 1993 Sep; 3(5):255-60. PubMed ID: 8400607
[TBL] [Abstract][Full Text] [Related]
31. Low serum levels of undercarboxylated osteocalcin in postmenopausal osteoporotic women receiving an inhibitor of bone resorption.
Aonuma H; Miyakoshi N; Hongo M; Kasukawa Y; Shimada Y
Tohoku J Exp Med; 2009 Jul; 218(3):201-5. PubMed ID: 19561390
[TBL] [Abstract][Full Text] [Related]
32. Comparison of serum and urinary C-terminal telopeptide of type I collagen in aging, menopause and osteoporosis.
Kawana K; Takahashi M; Hoshino H; Kushida K
Clin Chim Acta; 2002 Feb; 316(1-2):109-15. PubMed ID: 11750280
[TBL] [Abstract][Full Text] [Related]
33. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
Garnero P; Shih WJ; Gineyts E; Karpf DB; Delmas PD
J Clin Endocrinol Metab; 1994 Dec; 79(6):1693-700. PubMed ID: 7989477
[TBL] [Abstract][Full Text] [Related]
34. Serum levels of cross-linked N-telopeptides and aminoterminal propeptides of type I collagen indicate low bone mineral density in elderly women.
Scariano JK; Glew RH; Bou-Serhal CE; Clemens JD; Garry PJ; Baumgartner RN
Bone; 1998 Nov; 23(5):471-7. PubMed ID: 9823455
[TBL] [Abstract][Full Text] [Related]
35. High bone turnover is associated with low bone mass in both pre- and postmenopausal women.
Ravn P; Fledelius C; Rosenquist C; Overgaard K; Christiansen C
Bone; 1996 Sep; 19(3):291-8. PubMed ID: 8873970
[TBL] [Abstract][Full Text] [Related]
36. Higher efficacy of urinary bone resorption marker measurements in assessing response to treatment for osteoporosis in postmenopausal women.
Abe Y; Ishikawa H; Fukao A
Tohoku J Exp Med; 2008 Jan; 214(1):51-9. PubMed ID: 18212487
[TBL] [Abstract][Full Text] [Related]
37. Urinary cross-linked N-telopeptides of type I collagen and bone metabolic diseases.
Xue Y; Jia W; Zhang H; Dong J; Clemens JD; Tian X
Chin Med J (Engl); 1999 Feb; 112(2):149-52. PubMed ID: 11593583
[TBL] [Abstract][Full Text] [Related]
38. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group.
Ravn P; Clemmesen B; Christiansen C
Bone; 1999 Mar; 24(3):237-44. PubMed ID: 10071916
[TBL] [Abstract][Full Text] [Related]
39. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine.
Guo CY; Weetman AP; Eastell R
Clin Endocrinol (Oxf); 1997 Mar; 46(3):301-7. PubMed ID: 9156039
[TBL] [Abstract][Full Text] [Related]
40. Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment.
Gertz BJ; Clemens JD; Holland SD; Yuan W; Greenspan S
Calcif Tissue Int; 1998 Aug; 63(2):102-6. PubMed ID: 9685512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
